GlassScriptPhysician profile
Joseph Anderson
NPI 1629146154
$7,894.53
in general payments reported to CMS, 2019-2025
70 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $239 · 2021: $104 · 2022: $1,228 · 2023: $1,674 · 2024: $1,662 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,011 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,011.12 |
| Education | $205.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $526.24 | 2019-2025 | |
| Janssen Biotech, INC. | $463.34 | 2019-2025 | Rybrevant, Talvey, Darzalex |
| Genentech USA, INC. | $410.49 | 2019-2025 | Tecentriq, Alecensa, Rozlytrek |
| Pfizer INC. | $371.12 | 2019-2025 | |
| Genzyme Corporation | $367.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $366.22 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $300.07 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Coherus Oncology, INC. | $287.69 | 2022-2023 | |
| Amgen INC. | $286.82 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Kite Pharma, INC. | $237.37 | 2019-2023 | Yescarta |
| Geron Corporation | $211.88 | 2025 | Rytelo |
| Daiichi Sankyo INC. | $197.51 | 2020-2025 | Datroway, Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $196.18 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Array Biopharma INC | $196.09 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Eisai INC. | $188.99 | 2019-2024 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.